CELL-MEDIATED IMMUNITY IN PATIENTS WITH CERVICAL CANCER ON IMMUNOTHERAPY

  • Alexander Fedorovich Lazarev Altai Affiliation, N. N. Blokhin RCRC, RAMS
  • Dinara Kumarovna Kenbayeva Aslana City Cancer Clinic
  • Zukhra Alpysbayevna Manambayeva Semey State Medical University

Abstract

A total of 37 patients with stage III cervical cancer were examined to determine specific features in contents of blood and tumor tissue immunocompetent cells in cervical cancer patients receiving immunotherapy. The females were divided into 2 groups depending on receiving radiotherapy or combined radio- and immunotherapy by reinfusion of in vitro activated autolymphocytes plus recombinant interleukin-2 and Flogenzyme. Changes in contents of some lymphocyte differentiation clusters in blood and tumor biopsies were studied during treatment. After treatment completion the immunotherapy group demonstrated a statistically significant increase in levels of lymphocytes and their populations in blood and tumor tissue. Increase in cytotoxic lymphocyte levels was most marked which was suggestive of activation of antitumor immunity mechanisms.

Author Biographies

Alexander Fedorovich Lazarev, Altai Affiliation, N. N. Blokhin RCRC, RAMS

MD, PhD, DSc, Professor, Director,
Altai Affiliation, N. N. Blokhin RCRC, RAMS
(77, ut. Nikitina, Barnaul, RF, 656000)

Dinara Kumarovna Kenbayeva, Aslana City Cancer Clinic

MD, PhD, Head, Gynecology Department,
Aslana City Cancer Clinic
(3, ul. Makhmutkuli, Astana, Republic of Kazakhstan, 010000}

Zukhra Alpysbayevna Manambayeva, Semey State Medical University

MD, PhD, DSc, Head, Oncology Chair,
Semey State Medical University
(103, ul. Abaya Kunanbayeva, Semey, Republic of Kazakhstan, 014700)

References

1. Perez С. А., Santos Е. S., Raez L. Е. Active immunotherapy for non-small-cell lung cancer: moving toward a reality // Expert. Rev. AnticancerTher. — 2011. — Vol. 11,N 10. — P. 1599—1605.
2. Seremet Т., Brasseur F., Coulie P. G. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy // Cancer J, — 2011. — Vol. 17, N5. — P. 325— 330.
3. Козлов В. К., Молчанов О. Е., Жаринов Г. М. Иммунотерапия рекомбинантными цитокинами в лечении онкологических больных // Успехи клинической иммунологии и аллергологии. Том III / Под ред. А. В. Караулова. — М.: Изд-во регионального отделения РАЕН, 2002. — С. 263—279.
4. Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins / Galustian C., Vyakarnam A., Elhage O., Hickman O., Dasgupta Р., Smith R. A. // Biochem. Soc. Trans. — 201 1. — Vol. 39, N 5. — P. 1433— 1436.
5. Thibodeaux S. R., Curiel T. J. Immune therapy for ovarian cancer: promise and pitfalls // Int. Rev. Immunol. — 201 1. — Vol. 30, N 2—3. — P. 102—119.
6. Human papillomavlras vaccines: new tools for accelerating cervical cancer preventlon in developing countries / Luciani S., Jauregui В., Kleny C., Andrus J. K. // Immunotherapy. — 2009. — Vol. 1, N 5. — P. 795—807.
7. Tay S. K. Cervical cancer in the human papillomavirus vaccination era // Curr. Opin. Obstet. Gynecol. — 2012. — Vol. 24, N 1. — P. 3—7.
8. Субпопуляции опухоль-инфильтрирующих лимфоцитов серозной аденокарциномы яичников / Каирбаева М. Ж., Зуева Е. В., Моженкова А. В., Кокосадзе Н. В., Никогосян С. О., Тупицын Н. Н. // Тез. докл. Академии наук. — 2009. — Т. 429, № 1. — С. 1 15 — 1 19.
9. Yannelli J. R., Wroblewski J. М. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy // Vaccine. — 2004. — Vol. 23, N 1. — P. 97—113.
Published
2012-07-16
Section
Clinical observations